



UNITED STATES DEPARTMENT OF COMMERCE
Patent and Trademark Office

Address: COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20231

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	J	ATTORNEY/DISCUSSION NO.
08/907,041	08/06/97	GREENBERGER		

HM32/1206

FOLEY AND LARDNER
SUITE 500
3000 K STREET NW
WASHINGTON DC 20007-5109

CHEN, S EXAMINER

1 ART UNIT PAPER NUMBER

12/06/99

DATE MAILED:

Please find below and/or attached an Office communication concerning this application or proceeding.

Commissioner of Patents and Trademarks



UNITED STATES DEPARTMENT OF COMMERCE

Patent and Trademark Office

ASSISTANT SECRETARY AND COMMISSIONER
OF PATENTS AND TRADEMARKS
Washington, D C 20231

Paper No. 18

Stephen A. Bent
Foley & Lardner
3000 K Street, NW, Suite 500
Washington, DC 20007-5109

In re Application of :
Joel S. Greenberger :
Serial No. 08/907,041 :
Filed: August 6, 1997 : DECISION ON PETITION
For: PROTECTION FROM IONIZING :
RADIATION OR CHEMOTHERAPEUTIC :
DRUG DAMAGE BY IN VIVO GENE :
THERAPY :
:

This is a decision on the petition under 37 CFR 1.103(a), filed September 17, 1999, for Suspension of Prosecution in the instant application.

Applicants request suspension of prosecution to allow supplemental experimentation that applicant asserts will establish that claimed recombinant vectors provide a therapeutic effect. The supplemental experimentation involves *in vivo* administration of vectors representative of the scope of the invention.

Suspension of Action as delineated in 37 CFR 1.103, will be granted for good and sufficient cause (emphasis added) and for a reasonable time. In considering applicant's petition to suspend action, it is considered that applicant's efforts to show *in vivo* applicability will help in advancing prosecution of the instant application. Accordingly, the petition is GRANTED, and prosecution is suspended for a period of SIX (6) MONTHS from the date of mailing of this letter.

Should applicant desire to request an additional suspension beyond the 6 months requested, applicant must include with the petition evidence of progress to that time in fulfilling the objectives of the supplemental experimentation. Such evidence should include a description of the protocol of the experiments, the vectors tested and the results of the testing to that time.

George C. Elliott, Jr.

John Doll,
Director
Technology Center 1600